http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 05 Aug 2026 07:25:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html <p align="justify">WINNIPEG, Manitoba, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane” or the “Company”), announces that it has retained DNA Advisors Inc. (“DNA Advisors”) as its exclusive financial advisor to support a comprehensive review of strategic opportunities aimed at enhancing shareholder value and advancing the Company&apos;s long-term growth objectives.</p> <p align="justify">The strategic review process will evaluate a range of alternatives that may strengthen the Company&apos;s position and accelerate value creation, including potential strategic partnerships, financing initiatives, business development opportunities, acquisitions, commercial collaborations, and other corporate transactions.</p> <p align="justify">revyve® Antimicrobial Wound Gel and http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html Wed, 05 Aug 2026 07:25:00 -0400 A.17150087 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html <p align="justify">WINNIPEG, Manitoba, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane” or the “Company”), announces that it has retained DNA Advisors Inc. (“DNA Advisors”) as its exclusive financial advisor to support a comprehensive review of strategic opportunities aimed at enhancing shareholder value and advancing the Company&apos;s long-term growth objectives.</p> <p align="justify">The strategic review process will evaluate a range of alternatives that may strengthen the Company&apos;s position and accelerate value creation, including potential strategic partnerships, financing initiatives, business development opportunities, acquisitions, commercial collaborations, and other corporate transactions.</p> <p align="justify">revyve® Antimicrobial Wound Gel and http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html Wed, 05 Aug 2026 07:25:00 -0400 A.17150087 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html <p align="justify">WINNIPEG, Manitoba, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane” or the “Company”), announces that it has retained DNA Advisors Inc. (“DNA Advisors”) as its exclusive financial advisor to support a comprehensive review of strategic opportunities aimed at enhancing shareholder value and advancing the Company&apos;s long-term growth objectives.</p> <p align="justify">The strategic review process will evaluate a range of alternatives that may strengthen the Company&apos;s position and accelerate value creation, including potential strategic partnerships, financing initiatives, business development opportunities, acquisitions, commercial collaborations, and other corporate transactions.</p> <p align="justify">revyve® Antimicrobial Wound Gel and http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html Wed, 05 Aug 2026 07:25:00 -0400 A.17150087 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html <p align="justify">WINNIPEG, Manitoba, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane” or the “Company”), announces that it has retained DNA Advisors Inc. (“DNA Advisors”) as its exclusive financial advisor to support a comprehensive review of strategic opportunities aimed at enhancing shareholder value and advancing the Company&apos;s long-term growth objectives.</p> <p align="justify">The strategic review process will evaluate a range of alternatives that may strengthen the Company&apos;s position and accelerate value creation, including potential strategic partnerships, financing initiatives, business development opportunities, acquisitions, commercial collaborations, and other corporate transactions.</p> <p align="justify">revyve® Antimicrobial Wound Gel and http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html Wed, 05 Aug 2026 07:25:00 -0400 A.17150087 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html <p align="justify">WINNIPEG, Manitoba, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane” or the “Company”), announces that it has retained DNA Advisors Inc. (“DNA Advisors”) as its exclusive financial advisor to support a comprehensive review of strategic opportunities aimed at enhancing shareholder value and advancing the Company&apos;s long-term growth objectives.</p> <p align="justify">The strategic review process will evaluate a range of alternatives that may strengthen the Company&apos;s position and accelerate value creation, including potential strategic partnerships, financing initiatives, business development opportunities, acquisitions, commercial collaborations, and other corporate transactions.</p> <p align="justify">revyve® Antimicrobial Wound Gel and http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html Wed, 05 Aug 2026 07:25:00 -0400 A.17150087 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html <p align="justify">WINNIPEG, Manitoba, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane” or the “Company”), announces that it has retained DNA Advisors Inc. (“DNA Advisors”) as its exclusive financial advisor to support a comprehensive review of strategic opportunities aimed at enhancing shareholder value and advancing the Company&apos;s long-term growth objectives.</p> <p align="justify">The strategic review process will evaluate a range of alternatives that may strengthen the Company&apos;s position and accelerate value creation, including potential strategic partnerships, financing initiatives, business development opportunities, acquisitions, commercial collaborations, and other corporate transactions.</p> <p align="justify">revyve® Antimicrobial Wound Gel and http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html Wed, 05 Aug 2026 07:25:00 -0400 A.17150087 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html <p align="justify">WINNIPEG, Manitoba, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane” or the “Company”), announces that it has retained DNA Advisors Inc. (“DNA Advisors”) as its exclusive financial advisor to support a comprehensive review of strategic opportunities aimed at enhancing shareholder value and advancing the Company&apos;s long-term growth objectives.</p> <p align="justify">The strategic review process will evaluate a range of alternatives that may strengthen the Company&apos;s position and accelerate value creation, including potential strategic partnerships, financing initiatives, business development opportunities, acquisitions, commercial collaborations, and other corporate transactions.</p> <p align="justify">revyve® Antimicrobial Wound Gel and http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html Wed, 05 Aug 2026 07:25:00 -0400 A.17150087 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html <p align="justify">WINNIPEG, Manitoba, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane” or the “Company”), announces that it has retained DNA Advisors Inc. (“DNA Advisors”) as its exclusive financial advisor to support a comprehensive review of strategic opportunities aimed at enhancing shareholder value and advancing the Company&apos;s long-term growth objectives.</p> <p align="justify">The strategic review process will evaluate a range of alternatives that may strengthen the Company&apos;s position and accelerate value creation, including potential strategic partnerships, financing initiatives, business development opportunities, acquisitions, commercial collaborations, and other corporate transactions.</p> <p align="justify">revyve® Antimicrobial Wound Gel and http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html Wed, 05 Aug 2026 07:25:00 -0400 A.17150087 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html <p align="justify">WINNIPEG, Manitoba, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane” or the “Company”), announces that it has retained DNA Advisors Inc. (“DNA Advisors”) as its exclusive financial advisor to support a comprehensive review of strategic opportunities aimed at enhancing shareholder value and advancing the Company&apos;s long-term growth objectives.</p> <p align="justify">The strategic review process will evaluate a range of alternatives that may strengthen the Company&apos;s position and accelerate value creation, including potential strategic partnerships, financing initiatives, business development opportunities, acquisitions, commercial collaborations, and other corporate transactions.</p> <p align="justify">revyve® Antimicrobial Wound Gel and http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html Wed, 05 Aug 2026 07:25:00 -0400 A.17150087 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html <p align="justify">WINNIPEG, Manitoba, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane” or the “Company”), announces that it has retained DNA Advisors Inc. (“DNA Advisors”) as its exclusive financial advisor to support a comprehensive review of strategic opportunities aimed at enhancing shareholder value and advancing the Company&apos;s long-term growth objectives.</p> <p align="justify">The strategic review process will evaluate a range of alternatives that may strengthen the Company&apos;s position and accelerate value creation, including potential strategic partnerships, financing initiatives, business development opportunities, acquisitions, commercial collaborations, and other corporate transactions.</p> <p align="justify">revyve® Antimicrobial Wound Gel and http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html Wed, 05 Aug 2026 07:25:00 -0400 A.17150087 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html <p align="justify">WINNIPEG, Manitoba, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane” or the “Company”), announces that it has retained DNA Advisors Inc. (“DNA Advisors”) as its exclusive financial advisor to support a comprehensive review of strategic opportunities aimed at enhancing shareholder value and advancing the Company&apos;s long-term growth objectives.</p> <p align="justify">The strategic review process will evaluate a range of alternatives that may strengthen the Company&apos;s position and accelerate value creation, including potential strategic partnerships, financing initiatives, business development opportunities, acquisitions, commercial collaborations, and other corporate transactions.</p> <p align="justify">revyve® Antimicrobial Wound Gel and http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html Wed, 05 Aug 2026 07:25:00 -0400 A.17150087 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html <p align="justify">WINNIPEG, Manitoba, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane” or the “Company”), announces that it has retained DNA Advisors Inc. (“DNA Advisors”) as its exclusive financial advisor to support a comprehensive review of strategic opportunities aimed at enhancing shareholder value and advancing the Company&apos;s long-term growth objectives.</p> <p align="justify">The strategic review process will evaluate a range of alternatives that may strengthen the Company&apos;s position and accelerate value creation, including potential strategic partnerships, financing initiatives, business development opportunities, acquisitions, commercial collaborations, and other corporate transactions.</p> <p align="justify">revyve® Antimicrobial Wound Gel and http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html Wed, 05 Aug 2026 07:25:00 -0400 A.17150087 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html <p align="justify">WINNIPEG, Manitoba, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane” or the “Company”), announces that it has retained DNA Advisors Inc. (“DNA Advisors”) as its exclusive financial advisor to support a comprehensive review of strategic opportunities aimed at enhancing shareholder value and advancing the Company&apos;s long-term growth objectives.</p> <p align="justify">The strategic review process will evaluate a range of alternatives that may strengthen the Company&apos;s position and accelerate value creation, including potential strategic partnerships, financing initiatives, business development opportunities, acquisitions, commercial collaborations, and other corporate transactions.</p> <p align="justify">revyve® Antimicrobial Wound Gel and http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html Wed, 05 Aug 2026 07:25:00 -0400 A.17150087 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html <p align="justify">WINNIPEG, Manitoba, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane” or the “Company”), announces that it has retained DNA Advisors Inc. (“DNA Advisors”) as its exclusive financial advisor to support a comprehensive review of strategic opportunities aimed at enhancing shareholder value and advancing the Company&apos;s long-term growth objectives.</p> <p align="justify">The strategic review process will evaluate a range of alternatives that may strengthen the Company&apos;s position and accelerate value creation, including potential strategic partnerships, financing initiatives, business development opportunities, acquisitions, commercial collaborations, and other corporate transactions.</p> <p align="justify">revyve® Antimicrobial Wound Gel and http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Engagement+of+DNA+Advisors/26870276.html Wed, 05 Aug 2026 07:25:00 -0400 A.17150087 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Press+Releases/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140 http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html <p align="justify">WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.</p> <p align="justify">A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting.</p> <p align="justify">All matters voted upon at the Meeting were approved by shareholders, as detailed below.</p> <p align="justify"><strong>Election of Directors</strong></p> <p align="justify">All six nominees listed in http://www.streetinsider.com/Globe+Newswire/Kane+Biotech+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26723993.html Thu, 02 Jul 2026 07:25:00 -0400 A.17150087 A.30400265 A.36078215 KNBIF KNE O.02540339 O.02555813 O.34929518 O.49066140